Toggle menu

ENCEPH UK Study

Start date:
March 2015
End date:
December 2015 (Close to recruitment)
Co-ordinated by:
Brain Infections UK, University of Liverpool
Main trial site:
http://www.encephuk.org/studies

To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.

 

Aim

To produce a predictive tool for HSV encephalitis based on the early clinical features, by comparing the clinical features of those with and without HSV encephalitis.

Trial Design

A Prospective multi-centre cohort observational study.

Eligibility criteria (summary of )

Patients who present to the Emergency Department or Acute Medical Unit with suspected encephalitis

Chief Investigator

Professor Tom Solomon

Local PI

Dr Matt Reed

Research Team

EMERGE Research team in collaboration with the Acute Medical Unit (AMU), Critical Care and the Virology team at the RIE

Further information

For more information please refer to main trial website  

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Polly Black

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

More EMERGE Trials

The RECOVERY Trial

Randomised Evaluation of COVID-19 Therapy

Diagnostics devices play an important part in the clinical assessment of a patient’s health and treatment. The purpose of the study is the evaluation of a new diagnostic platform developed by LumiraDx. The evaluation is focused around various biomarkers useful in the emergency settings.

Read more

NOVEL Study

Collection of venous and capillary blood samples for the evaluation of new diagnostic devices for cardiovascular conditions

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study